Recap and Update of Positive Data from Phase Ib/II Clinical Trials of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Presented at the 2019 American Society of Hematology (ASH) Annual Meeting in Orlando

NEXT STORY
BioAegis Therapeutics Announces Publication: “Delayed Administration of Recombinant Plasma Gelsolin Improves Survival in a Murine Model of Severe Influenza”
PREV STORY
Press release Swedish financier Mats Gabrielsson becomes major shareholder in Oncology Venture
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Oxford Biomedica Signs Supply Agreement with AstraZeneca to Expand Manufacturing Support of COVID-19 Vaccine Candidate, AZD1222

author_avatar
NASDAQ Market News

TG Therapeutics Presents Positive Interim Data from UNITY-NHL Phase 2b Trial Evaluating Umbralisib Monotherapy in Patients with Marginal Zone Lymphoma at the 55th American Society of Clinical Oncology (ASCO) Annual Meeting

author_avatar
NASDAQ Market News

Industry Leaders Marshall Votta, Josh Holmes and Laura Sandman Join RowdMap, Inc. in Key Market Roles to Continue Growth across 48 States, Covering over 100MM Patients

LOUISVILLE, Ky., May 2, 2016 (GLOBE NEWSWIRE) -- via PRWEB - Marshall Votta, Josh ...

author_avatar
NASDAQ Market News